Please refer to our Privacy policy for important information on the use of cookies. By continuing to use this website, you agree to this.

Press Release

News and Media - Interserve

Interserve Construction named as preferred bidder for new £15m Medicines Manufacturing Innovation Centre

by Interserve Press Office | Jul 17, 2020

Interserve Construction named as preferred bidder for new £15m Medicines Manufacturing Innovation CentreInterserve Group Limited, the international support services, construction and equipment group, has been named as preferred bidder for the new £15 million Medicines Manufacturing Innovation Centre (MMIC) in Inchinnan, Renfrewshire.

The state-of-the-art development will be located near Glasgow Airport and will be led by CPI in partnership with The University of Strathclyde, Scottish Enterprise, and founding industry partners, AstraZeneca and GlaxoSmithKline.

The centre will ensure the UK is a technology and innovation leader in small molecule pharmaceutical and fine chemical manufacturing, thereby boosting the competitiveness of both sectors.

With a collaborative innovation culture and state-of the art facilities, the new Medicines Manufacturing Innovation Centre will develop highly efficient and effective technologies. As a flexible and adaptable building, the centre will enable industry, academia, healthcare providers and regulators to work collaboratively to address challenges along the medicines supply chain.

The new manufacturing centre is funded by several sources including UK Research and Innovation through the UK Industrial Strategy Challenge Fund, Scottish Enterprise and founding industry partners GlaxoSmithKline and AstraZeneca.

Cameron Stewart, Regional Director at Interserve Construction said: “The new centre at Inchinnan is a really exciting, innovative project where our strengths in the medical sector will hugely benefit the project.

“Interserve Construction will bring our considerable experience and capabilities in delivering similar projects like the National Biologics Manufacturing Centre for CPI in Darlington, which is currently supporting efforts to manufacture and formulate vaccines for COVID-19, and the Jack Copeland Centre in Edinburgh for the Scottish National Blood Transfusion Service. The Medicines Manufacturing Innovation Centre will be market leading for the pharmaceutical industry and we are delighted that will be part of that.”

Nigel Perry, Chief Executive Officer at CPI, said: “The Medicines Manufacturing Innovation Centre will enhance the UK’s existing competitive advantage by deepening the skills base and strengthening the rationale for companies to invest in new, highly productive medicines manufacturing.

“CPI is delighted to be working alongside the University of Strathclyde, Innovate UK, Scottish Government and our industry partners to deliver this globally unique centre that will prepare the pharmaceutical supply chain for vital, next generation medicines and further extend CPI’s healthcare capabilities.”

Scottish Government Minister for Business, Innovation and Energy, Paul Wheelhouse, said: “I am delighted that the Medicines Manufacturing Innovation Centre will be located in Scotland, given its potential to become a global centre of excellence and bringing significant benefits to Scotland’s economy. The location of the MMIC is also a very positive endorsement of Scotland’s Life and Chemical Science sectors and will build on our internationally recognised strengths in both Research and Development and manufacturing.”


For more information contact:

Ian Green
Corporate Affairs Manager (Interserve Construction)
Telephone: 07740 513535

About Interserve Group Limited

Interserve Group Limited is one of the world’s foremost support services and construction companies. We offer design, construction, equipment, facilities management and frontline public services. We are headquartered in the UK and have consolidated revenues of £2.9bn and a workforce of circa 53,500 people worldwide.

For Interserve news follow: @interserve

Share this